Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · see citing works

U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923 · see citing works

Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial

(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807 · see citing works

Epidemiology of severe hypoglycemia in the diabetes control and complications trial

(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807 · see citing works

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

(1995) · Diabetes · doi:10.2337/diabetes.44.11.1249 · Cited by 796 · see citing works

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654 · see citing works

Efficacy of Metformin in Type II Diabetes

Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519 · see citing works

Postprandial Blood Glucose

Association, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.775 · Cited by 464 · see citing works

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264 · see citing works

Standards of Medical Care for Patients With Diabetes Mellitus

American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s33 · Cited by 262 · see citing works

Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial

Henry, R. R., Gumbiner, B., Ditzler, T., Wallace, P., Lyon, R., & Glauber, H. S. (1993) · Diabetes Care · doi:10.2337/diacare.16.1.21 · Cited by 227 · see citing works

Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus

Avilés-Santa, L. M., Sinding, J., & Raskin, P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00004 · Cited by 222 · see citing works

Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin

Young, A. A., Gedulin, B. R., Vine, W., Percy, A., & RINK, T. J. (1995) · Diabetologia · doi:10.1007/bf00401833 · Cited by 184 · see citing works

Dose-response for glucagonostatic effect of amylin in rats

Gedulin, B. R., RINK, T. J., & Young, A. A. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90170-0 · Cited by 180 · see citing works

Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: A Physiological Approach Toward Improved Metabolic Control

Weyer, C., Maggs, D., Young, A., & Kolterman, O. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397357 · Cited by 175 · see citing works

Inhibition of Central Amylin Signaling Increases Food Intake and Body Adiposity in Rats

Rushing, P. A., Hagan, M. M., Seeley, R. J., Lutz, T. A., D’Alessio, D. A., Air, E. L., & Woods, S. C. (2001) · Endocrinology · doi:10.1210/endo.142.11.8593 · Cited by 173 · see citing works

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double‐blind, placebo‐controlled study

Finer, N., Bloom, S. R., Frost, G. S., Banks, L. M., & Griffiths, J. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00071.x · Cited by 171 · see citing works

Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes

Ratner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924094 · Cited by 156 · see citing works

Frequency and Symptoms of Hypoglycaemia Experienced by Patients with Type 2 Diabetes Treated with Insulin

Hepburn, D. A., MacLeod, K. M., Pell, A. C. H., Scougal, I. J., & Frier, B. M. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb00050.x · Cited by 155 · see citing works

The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus

Fineman, M. S., Weyer, C., Maggs, D. G., Strobel, S. A., & Kolterman, O. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-34790 · Cited by 147 · see citing works

Amylin decreases food intake in mice

Morley, J. E., & Flood, J. F. (1991) · Peptides · doi:10.1016/0196-9781(91)90148-i · Cited by 137 · see citing works

Perceived symptoms of hypoglycaemia in elderly Type 2 diabetic patients treated with insulin

Jaap, A. J., Jones, G. C., McCrimmon, R. J., Deary, I. J., & Frier, B. M. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199805)15:5 · Cited by 134 · see citing works

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., & KLEIN, P. D. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00311.x · Cited by 112 · see citing works

Unresolved Challenges with Insulin Therapy in Type 1 and Type 2 Diabetes: Potential Benefit of Replacing Amylin, a Second β -Cell Hormone

Edelman, S. V., & Weyer, C. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150260007390 · Cited by 74 · see citing works

Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy

Buse, J. B., Weyer, C., & Maggs, D. G. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.3.137 · Cited by 71 · see citing works

Pramlintide: A Human Amylin Analogue Reduced Postprandial Plasma Glucose, Insulin, and C-peptide Concentrations in Patients with Type 2 Diabetes

Thompson, R., Gottlieb, A., Organ, K., Koda, J., Kisicki, J. C., & Kolterman, O. (1997) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199707)14:7 · Cited by 69 · see citing works

The Medical Management of Hyperglycemia Over a 10-Year Period in People With Diabetes

Klein, R., Klein, R., Moss, S. E., & Cruickshanks, K. J. (1996) · Diabetes Care · doi:10.2337/diacare.19.7.744 · Cited by 61 · see citing works

Postprandial hyperglycaemic state: importance and consequences.

Lebovitz, H. E. (1998) · PubMed · Cited by 59 · see citing works

The Cgrp Family: Calcitonin Gene-Related Peptide (Cgrp), Amylin and Adrenomedullin

Poyner, D. R. (1999) · Research Portal (King's College London) · Cited by 34 · see citing works

Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy

Gürlek, A., Erbas, T. A., & Gedik, O. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1212102 · Cited by 32 · see citing works

Editorial

(1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00039-4 · Cited by 23 · see citing works

Should Obese Type 2 Diabetic Patients be Treated with Insulin?

Riddle, M. C. (2001) · doi:10.1002/9780470757109.ch7 · Cited by 7 · see citing works

Analysis: Pramlintide: An Agent for Glycemic Control Plus Weight Control?

Riddle, M. C. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924102 · Cited by 4 · see citing works

9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetes—2022</i>

American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555 · see citing works

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · see citing works

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,195 · see citing works

9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Care in Diabetes—2023</i>

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851 · see citing works

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699 · see citing works

Update on the treatment of type 2 diabetes mellitus

Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647 · see citing works

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation

Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581 · see citing works

Diabetes mellitus and periodontal disease

Mealey, B. L., & Ocampo, G. L. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00193.x · Cited by 565 · see citing works

Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of <i>The Obesity Society</i> and the <i>American Society of Hypertension</i>

Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528 · see citing works

Central Control of Body Weight and Appetite

Woods, S. C., & D’Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 460 · see citing works

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0316-2 · Cited by 420 · see citing works

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Holt, R., DeVries, J., Hess-Fischl, A., Hirsch, I., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 1,374 · see citing works

Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity

Akbari, P., Gilani, A., Sosina, O., Kosmicki, J. A., Khrimian, L., Fang, Y.-Y., Persaud, T., Garcia, V., Sun, D., Li, A., et al. (2021) · Science · doi:10.1126/science.abf8683 · Cited by 276 · see citing works

Discovery and characterization of smORF-encoded bioactive polypeptides

Saghatelian, A., & Couso, J. P. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1964 · Cited by 286 · see citing works

Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension

Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D. M., & Sowers, J. R. (2012) · Obesity · doi:10.1002/oby.20181 · Cited by 286 · see citing works

Pharmacotherapy of obesity: available medications and drugs under investigation.

Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248 · see citing works

Amylin Agonists: A Novel Approach in the Treatment of Diabetes

Schmitz, O., Brock, B., & Rungby, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s233 · Cited by 237 · see citing works

Effects of PYY[3–36] in rodent models of diabetes and obesity

Pittner, R. A., Moore, C. X., Bhavsar, S., Gedulin, B. R., Smith, P. A., Jodka, C. M., Parkes, D. G., Paterniti, J. R., Srivastava, V. P., & Young, A. A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802696 · Cited by 217 · see citing works

The obesity pipeline: current strategies in the development of anti-obesity drugs

Cooke, D., & Bloom, S. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 212 · see citing works

Relationship of Baseline HbA1c and Efficacy of Current Glucose Lowering Therapies: A Meta-Analysis of Randomised Clinical Trials

DeFronzo, R. A., Stonehouse, A. H., Han, J., & Wintle, M. E. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02941.x · Cited by 214 · see citing works

The role of gut hormones in the regulation of body weight and energy homeostasis

Karra, E., & Batterham, R. L. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 210 · see citing works

The Impact of Diabetes and Diabetes Medications on Bone Health

Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 210 · see citing works

Diabetes Mellitus: Pathogenesis and Treatment Strategies

Skyler, J. S. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306273 · Cited by 208 · see citing works

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205 · see citing works

The endocrinology of food intake

Begg, D. P., & Woods, S. C. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.136 · Cited by 199 · see citing works

Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients

Hollander, P. A., Maggs, D. G., Ruggles, J. A., Fineman, M. S., Shen, L. Z., Kolterman, O., & Weyer, C. (2004) · Obesity Research · doi:10.1038/oby.2004.76 · Cited by 191 · see citing works

Ion Mobility Spectrometry–Mass Spectrometry Defines the Oligomeric Intermediates in Amylin Amyloid Formation and the Mode of Action of Inhibitors

Young, L. M., Cao, P., Raleigh, D. P., Ashcroft, A. E., & Radford, S. E. (2013) · Journal of the American Chemical Society · doi:10.1021/ja406831n · Cited by 190 · see citing works

Obesity: Current and potential pharmacotherapeutics and targets

Narayanaswami, V., & Dwoskin, L. P. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 184 · see citing works

New Drugs for the Treatment of Diabetes

Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 187 · see citing works

Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study

Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · see citing works

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care · doi:10.2337/dc08-0029 · Cited by 172 · see citing works

Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus

Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 173 · see citing works

Metabolic Syndrome: From Global Epidemiology to Individualized Medicine

Batsis, J. A., Nieto-Martínez, R. E., & López-Jiménez, F. A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100355 · Cited by 168 · see citing works

Two-dimensional infrared spectroscopy reveals the complex behaviour of an amyloid fibril inhibitor

Middleton, C. T., Marek, P., Cao, P., Chiu, C., Singh, S., Woys, A. M., de Pablo, J. J., Raleigh, D. P., & Zanni, M. T. (2012) · Nature Chemistry · doi:10.1038/nchem.1293 · Cited by 169 · see citing works

Diabetes Mellitus: Pathogenesis and Treatment Strategies.

Skyler, J. S. (2004) · ChemInform · doi:10.1002/chin.200442237 · Cited by 165 · see citing works

Pramlintide in the treatment of type 1 and type 2 diabetes mellitus

Ryan, G. J., Jobe, L. J., & Martin, R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.009 · Cited by 159 · see citing works

Pharmacotherapy of type 2 diabetes: An update and future directions

DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 161 · see citing works

Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes

Ratner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology &amp; Therapeutics · doi:10.1089/15209150252924094 · Cited by 156 · see citing works

Diabetes medications and body weight

Mitri, J., & Hamdy, O. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903081725 · Cited by 136 · see citing works

Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes

WEINZIMER, S. A., Sherr, J. L., Cengiz, E., Kim, G. E., Ruiz, J., CARRIA, L. R., Voskanyan, G. R., Roy, A., & Tamborlane, W. V. (2012) · Diabetes Care · doi:10.2337/dc12-0330 · Cited by 134 · see citing works

Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition

Adler, B. L., Yarchoan, M. M., Hwang, H. M., Louneva, N., Blair, J. A., Palm, R. F., Smith, M. A., Lee, H., Arnold, S. E., & Casadesús, G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.076 · Cited by 131 · see citing works

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study

Smith, S. R., Blundell, J. E., Burns, C. M., Ellero, C., Schroeder, B. E., Kesty, N. C., Chen, K. S., Halseth, A. E., Lush, C. W., & Weyer, C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00217.2007 · Cited by 131 · see citing works

Can We Really Close the Loop and How Soon? Accelerating the Availability of an Artificial Pancreas: A Roadmap to Better Diabetes Outcomes

Kowalski, A. J. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0031 · Cited by 127 · see citing works

GLP-1 and Amylin in the Treatment of Obesity

Jorsal, T., Rungby, J., Knop, F. K., & Vilsbøll, T. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0693-3 · Cited by 124 · see citing works

Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin

Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc07-0589 · Cited by 116 · see citing works

Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?

Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113 · see citing works

Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1

Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108 · see citing works

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

Weyer, C., Gottlieb, A., Kim, D. D. H., Lutz, K., Schwartz, S. L., Gutiérrez, M. E. H., Wang, Y., Ruggles, J. A., Kolterman, O., & Maggs, D. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3074 · Cited by 107 · see citing works

Diabetes pharmacotherapy and effects on the musculoskeletal system

Kalaitzoglou, E., Fowlkes, J. L., Popescu, I. R., & Thrailkill, K. M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3100 · Cited by 101 · see citing works

Pramlintide and the treatment of diabetes: a review of the data since its introduction

Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 99 · see citing works

Current Management Strategies for Coexisting Diabetes Mellitus and Obesity

Scheen, A. J. (2003) · Drugs · doi:10.2165/00003495-200363120-00001 · Cited by 93 · see citing works

Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk

Hoogwerf, B. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87 · see citing works

Role of Amylin in Type 1 and Type 2 Diabetes

Hieronymus, L. B., & Griffin, S. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607642 · Cited by 86 · see citing works

Weight Beneficial Treatments for Type 2 Diabetes

Meneghini, L. F., Orozco‐Beltrán, D., Khunti, K. K., Caputo, S., Damçi, T., Liebl, A., & Ross, S. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1074 · Cited by 82 · see citing works

Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187

Gedulin, B. R., Jodka, C. M., Herrmann, K., & Young, A. A. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.06.004 · Cited by 81 · see citing works

Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes

Hollander, P. A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.3.159 · Cited by 81 · see citing works

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study

Maggs, D. G., Fineman, M. S., Kornstein, J., Burrell, T., Schwartz, S. L., Wang, Y., Ruggles, J. A., Kolterman, O., & Weyer, C. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.419 · Cited by 77 · see citing works

True or false? Alzheimer’s disease is type 3 diabetes: Evidences from bench to bedside

Peng, Y., Yao, S.-Y., Chen, Q., Jin, H., Du, M., Xue, Y.-H., & Liu, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102383 · Cited by 76 · see citing works

The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta‐analysis

Singh‐Franco, D., Pérez, A., & Harrington, C. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01337.x · Cited by 75 · see citing works

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus

Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 75 · see citing works

Present and Future: Pharmacologic Treatment of Obesity

Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 76 · see citing works

Neuroendocrine hormone amylin in diabetes

Zhang, X., Pan, Y.-H., Huang, Y., & Zhao, H. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i9.189 · Cited by 75 · see citing works

Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes

Ceriello, A., Piconi, L., Quagliaro, L., Wang, Y., Schnabel, C. A., Ruggles, J. A., Gloster, M., Maggs, D. G., & Weyer, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.632 · Cited by 75 · see citing works

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01185-7 · Cited by 80 · see citing works

Weight Management for Type 2 Diabetes Mellitus: Global Cardiovascular Risk Reduction

Lee, M., & Aronne, L. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.007 · Cited by 73 · see citing works

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

Mathiesen, D. S., Lund, A., Vilsbøll, T., Knop, F. K., & Bagger, J. I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.617400 · Cited by 72 · see citing works

Pramlintide for the Treatment of Insulin-Requiring Diabetes Mellitus

Kruger, D. F., & Gloster, M. (2004) · Drugs · doi:10.2165/00003495-200464130-00003 · Cited by 70 · see citing works

Pramlintide in the Treatment of Diabetes Mellitus

Edelman, S. V., Maier, H., & Wilhelm, K. (2008) · BioDrugs · doi:10.2165/0063030-200822060-00004 · Cited by 68 · see citing works

Peroxisome proliferator-activated receptor gamma agonists in renal disease

Iglesias, P., & Díez, J. J. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02134 · Cited by 68 · see citing works

Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes Mellitus

Langley, A., Suffoletta, T. J., & Jennings, H. R. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1163 · Cited by 64 · see citing works

Treatment Approach to Patients With Severe Insulin Resistance

Church, T., & Haines, S. T. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.97 · Cited by 67 · see citing works

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes

Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care · doi:10.2337/dc09-0395 · Cited by 66 · see citing works

Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes

Pullman, J. R., Darsow, T., & Frías, J. P. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.203 · Cited by 64 · see citing works

Obesity treatment: novel peripheral targets

Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64 · see citing works

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis

Maggs, D. G., Shen, L. Z., Strobel, S. A., Brown, D., Kolterman, O., & Weyer, C. (2003) · Metabolism · doi:10.1016/j.metabol.2003.06.003 · Cited by 63 · see citing works

Amylin-mediated control of glycemia, energy balance, and cognition

Mietlicki‐Baase, E. G. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.034 · Cited by 62 · see citing works

Obesity pharmacotherapy: What is next?

Colón‐González, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.005 · Cited by 61 · see citing works

Practical Use of Pharmacotherapy for Obesity

Igel, L. I., Kumar, R. B., Saunders, K. H., & Aronne, L. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.049 · Cited by 59 · see citing works

Recent Advances in Insulin Therapy

Wilson, L. M., & Castle, J. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0065 · Cited by 58 · see citing works

Addition of pramlintide to insulin therapy lowers HbA 1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

Hollander, P. A., Ratner, R. E., Fineman, M. S., Strobel, S. A., Shen, L. Z., Maggs, D. G., Kolterman, O., & Weyer, C. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00295.x · Cited by 58 · see citing works

Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases

Sonne, N., Karsdal, M. A., & Henriksen, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101109 · Cited by 57 · see citing works

Adjunct therapy for type 1 diabetes mellitus

Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 57 · see citing works

Aqueous extract of Abutilon indicum Sweet inhibits glucose absorption and stimulates insulin secretion in rodents

Krisanapun, C., Peungvicha, P., Temsiririrkkul, R., & Wongkrajang, Y. (2009) · Nutrition Research · doi:10.1016/j.nutres.2009.07.006 · Cited by 57 · see citing works

How Does Treatment Satisfaction Work?

Peyrot, M. F., & Rubin, R. R. (2009) · Diabetes Care · doi:10.2337/dc08-2256 · Cited by 56 · see citing works

Complications of Diabetes Therapy

Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 58 · see citing works

The Pharmacological Treatment and Management of Obesity

Hussain, S. S., & Bloom, S. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2243 · Cited by 53 · see citing works

Need for better diabetes treatment for improved renal outcome

Rossing, P. R., & de Zeeuw, D. (2011) · Kidney International · doi:10.1038/ki.2010.513 · Cited by 54 · see citing works

Role of Sequence and Structural Polymorphism on the Mechanical Properties of Amyloid Fibrils

Yoon, G., Lee, M., Kim, J. I., Na, S., & Eom, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088502 · Cited by 54 · see citing works

Investigating Endogenous Peptides and Peptidases Using Peptidomics

Tinoco, A. D., & Saghatelian, A. (2011) · Biochemistry · doi:10.1021/bi200417k · Cited by 52 · see citing works

Circulating Differentially Methylated Amylin DNA as a Biomarker of β-Cell Loss in Type 1 Diabetes

Olsen, J. A., Kenna, L. A., Spelios, M. G., Hessner, M. J., & Akirav, E. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152662 · Cited by 51 · see citing works

Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control

Vos, R. C., van Avendonk, M. J., Jansen, H., Goudswaard, A. N. N., van den Donk, M., Gorter, K. J., Kerssen, A., & Rutten, G. E. H. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006992.pub2 · Cited by 51 · see citing works

The Role of Pramlintide for Weight Loss

Dunican, K. C., Adams, N. M., & Desilets, A. R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m210 · Cited by 50 · see citing works

Regulation of appetite to treat obesity

Kim, G. W., Lin, J. E., Valentino, M. A., Colón‐González, F., & Waldman, S. A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.3 · Cited by 46 · see citing works

Natural products targeting inflammation-related metabolic disorders: A comprehensive review

Nainu, F., Frediansyah, A., Mamada, S., Permana, A., Salampe, M., Chandran, D., Emran, T. B., & Simal-gandara, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16919 · Cited by 40 · see citing works

Novel Pharmacologic Agents for Type 2 Diabetes

Uwaifo, G. I., & Ratner, R. E. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.006 · Cited by 45 · see citing works

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46 · see citing works

It Takes Two to Tango: Combined Amylin/Leptin Agonism as a Potential Approach to Obesity Drug Development

Chan, J. L., Roth, J. D., & Weyer, C. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181b91911 · Cited by 44 · see citing works

The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus.

Zarowitz, B., Tangalos, E., Hollenack, K., & O'Shea, T. (2006) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2006.01.002 · Cited by 42 · see citing works

Novel strategy for the use of leptin for obesity therapy

Tam, C. S., Lecoultre, V., & Ravussin, É. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.619974 · Cited by 46 · see citing works

Pramlintide acetate

McQueen, J. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050341 · Cited by 43 · see citing works

Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes

Ratner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology &amp; Therapeutics · doi:10.1089/15209150252924094 · Cited by 156 · see citing works

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264 · see citing works

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial

Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307 · see citing works

Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight

Karl, D. M., Philis‐Tsimikas, A., Darsow, T., Lorenzi, G. M., Kellmeyer, T., Lutz, K., Wang, Y., & Frías, J. P. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0013 · Cited by 38 · see citing works

How safe and effective is pramlintide in improving long-term glycemic control and weight loss in patients with type 2 diabetes mellitus receiving insulin?

Iyengar, S., Love, K. M., Bauerband, B., & Rodríguez, J. E. (2013) · Evidence-Based Practice · doi:10.1097/01.ebp.0000540473.91752.04